|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400081850 |
|
最近更新日期: Date of Last Refreshed on: |
2024-03-13 16:36:41 |
|
注册时间: Date of Registration: |
2024-03-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
膀胱粘膜卷管术治疗儿童原发性膀胱输尿管反流 |
|
Public title: |
Tubularized Bladder Mucosa Method for Treating Primary Vesicoureteral Reflux in Children |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
膀胱粘膜卷管术治疗儿童原发性膀胱输尿管反流 |
|
Scientific title: |
Tubularized Bladder Mucosa Method for Treating Primary Vesicoureteral Reflux in Children |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王川 |
研究负责人: |
王川 |
|
Applicant: |
Wang Chuan |
Study leader: |
Wang Chuan |
|
申请注册联系人电话: Applicant telephone: |
+86 152 0833 4378 |
研究负责人电话: Study leader's telephone: |
+86 152 0833 4378 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
724147911@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
724147911@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国成都市武侯区国学巷37号 |
研究负责人通讯地址: |
中国成都市武侯区国学巷37号 |
|
Applicant address: |
#37 Guo-Xue-Xiang, Wuhou District, Chengdu, China |
Study leader's address: |
#37 Guo-Xue-Xiang, Wuhou District, Chengdu, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital, Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital, Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024审(108)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Review Committee, West China Hospital, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-29 00:00:00 |
||
|
伦理委员会联系人: |
邓绍林 |
||
|
Contact Name of the ethic committee: |
Deng Shaolin |
||
|
伦理委员会联系地址: |
中国成都市武侯区国学巷37号 |
||
|
Contact Address of the ethic committee: |
#37 Guo-Xue-Xiang, Wuhou District, Chengdu, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8532 3237 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国成都市武侯区国学巷37号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
#37 Guo-Xue-Xiang, Wuhou District, Chengdu, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
华西医院院内SCI经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
West China Hospital SCI Funding |
||||||||||||||||||||||
|
Target disease: |
Vesicoureteral reflux |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
研究膀胱粘膜卷管术应用于治疗儿童原发性膀胱输尿管反流的有效性和安全性 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate safety and efficacy of tubularized bladder mucosa procedure in treating pediatric patients with primary vesicoureteral reflux |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
将需进行开放性膀胱内途径输尿管再植手术的患者分为两组,分别采用膀胱粘膜卷管术和Politano-Leadbetter术,比较预后。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Patients requiring intravesical open surgical reimplantation procedures are divided into two groups, and undergo tubularized bladder mucosa procedure and Politano-Leadbetter procedure, respectively. Outcomes of two groups are compared. |
||||||||||||||||||||||
|
纳入标准: |
1.经VCUG CUG或泌尿超声造影,明确诊断存在原发性膀胱输尿管反流患儿; 2.至少存在一种下列情形:①预防性口服抗生素治疗后出现突破性尿路感染;②肾图提示新肾瘢痕形成;③肾发育延迟;④预防性使用抗生素保守治疗至1岁后仍存在高级别反流。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. .Primary vesicoureteral reflux was confirmed by VCUG or excretory urinary contrast-enhanced ultrasound; 2. One of the following conditions exists: ①breakthrough urinary tract infection during prophylactic oral antibiotic treatment; ②nephrogram suggests new renal scar formation;③ delayed renal development; ④high grade of vesicoureteral reflux persisting in patients over 1 year old after conservative treatment with prophylactic antibiotics. |
||||||||||||||||||||||
|
排除标准: |
1.存在其他泌尿生殖系统畸形; 2.有排尿功能异常; 3.有排便功能异常; 4.继发性膀胱输尿管反流或膀胱输尿管反流术后复发者; 5.输尿管扩张明显,直径超过1cm 者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patient with other urogenital system malformations; 2. Patient with voiding dysfunction; 3. Patient with defecation dysfunction; 4. Patient with secondary vesicoureteral reflux or recurrent vesicoureteral reflux; 5. Ureterectasia exists and the diameter of the ureter is more than 1cm. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-03-11 00:00:00至 To 2025-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-03-25 00:00:00 至 To 2024-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
NA |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |